Cenobamate

Introduction Overview

Generic Name

cenobamate

Brand Name

Xcopri

Dosage Form

oral tablets (12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg)

Drug Class

Carbamate anticonvulsants

Pharmacokinetics

Absorption:
Cenobamate is well absorbed via the gastrointestinal tract following oral administration of Xcopri tablets. The drug exhibits predictable pharmacokinetics with dose-proportional increases in plasma concentrations over the therapeutic range. It achieves peak plasma concentrations typically within 1 to 4 hours post-dose. Food does not significantly affect the bioavailability of cenobamate, allowing administration with or without meals. This rapid and consistent absorption facilitates once-daily dosing and reliable seizure control.

Distribution:
Once absorbed, cenobamate is widely distributed throughout body tissues. It is moderately bound to plasma proteins, approximately around 60%, which allows sufficient free drug concentrations to exert pharmacological effects. The volume of distribution indicates that cenobamate penetrates the central nervous system effectively, which is critical for its anticonvulsant action. The ability to cross the blood-brain barrier ensures direct modulation of neuronal excitability in seizure foci.

Metabolism:
Cenobamate undergoes hepatic metabolism primarily via multiple cytochrome P450 enzymes, including CYP2C19 and CYP3A4/5. Metabolism produces several inactive metabolites excreted mainly in the urine. The involvement of CYP enzymes suggests potential drug-drug interactions, especially with other antiepileptic agents or medications metabolized via the same pathways. The metabolism rate influences the drug’s half-life and steady-state levels, necessitating cautious dose titration to avoid toxicity.

Elimination:
Cenobamate and its metabolites are predominantly eliminated renally. The elimination half-life in adults ranges from approximately 50 to 60 hours, supporting a convenient once-daily dosing regimen. Renal clearance accounts for the majority of drug excretion, with minimal fecal elimination. Patients with impaired renal function may require careful monitoring or dose adjustment given the clearance pathway. The extended half-life ensures stable plasma drug levels, contributing to steady seizure control and therapeutic efficacy.

Dosage Forms

Available Dosage Forms:
Xcopri is available exclusively as oral tablets formulated for once-daily administration. The tablets come in multiple strengths to allow for precise dose titration and maintenance therapy. Specific tablet strengths include 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg. These scored tablets can be swallowed whole or crushed to facilitate administration by mouth or via a nasogastric tube as an oral suspension.

Dosages for Adults and Adolescents:
- Initial Titration Phase (Weeks 1-2): 12.5 mg once daily
- Titration Phase (Weeks 3-4): Increase to 25 mg once daily
- Titration Phase (Weeks 5-6): Increase to 50 mg once daily
- Titration Phase (Weeks 7-8): Increase to 100 mg once daily
- Titration Phase (Weeks 9-10): Increase to 150 mg once daily
- Maintenance Phase (Week 11 onward): 200 mg once daily
- Maximum Dose: Up to 400 mg once daily based on clinical response and tolerability

This gradual titration schedule over at least 10 weeks is imperative to minimize risks of severe adverse reactions such as hypersensitivity and to optimize therapeutic outcomes. Careful upward titration in increments of 50 mg every two weeks is recommended.

Specific Patient Populations:
Xcopri is approved for use in adults with partial-onset seizures and is not recommended for use in pediatric populations under 18 years due to lack of established safety and efficacy. No specific dosing guidelines are currently established for patients with hepatic or renal impairment; however, cautious use and clinical monitoring are advised. Pregnant or breastfeeding women should only use Xcopri under strict medical supervision due to potential risks to the fetus and infant. Dose adjustments may be necessary in elderly patients due to possible altered pharmacokinetics or comorbidities. The ability to crush tablets and prepare oral suspensions also facilitates administration in patients having difficulty swallowing or requiring nasogastric feeding.

Mechanism Of Action

Cenobamate is classified as a carbamate anticonvulsant with a unique and multifaceted mechanism of action targeting neuronal hyperexcitability responsible for partial-onset seizures. Its primary molecular mechanism involves inhibition of voltage-gated sodium channels. By stabilizing the inactivated state of these channels, cenobamate prevents repetitive neuronal firing, reducing the propagation of abnormal electrical signals within focal epileptic networks.

In addition to modulating sodium channel activity, cenobamate enhances GABAergic neurotransmission. It acts as a positive allosteric modulator of GABAA ion channels, augmenting inhibitory synaptic transmission. This dual activity on sodium channels and GABA receptors promotes a balanced neuronal environment, counteracting excitatory overactivity that precipitates seizures.

At the biochemical level, cenobamate’s inhibition of persistent sodium currents decreases sustained depolarizations that can trigger epileptiform discharges. Its modulation of GABA-mediated chloride influx hyperpolarizes neurons further impeding excitatory impulses. Together, these actions suppress aberrant neuronal synchrony and seizure generation.

Clinically, this unique combination of mechanisms differentiates cenobamate from other antiepileptic drugs that may selectively target either sodium channels or GABAergic pathways alone. Comparative studies indicate that cenobamate’s efficacy in reducing partial-onset seizures is substantial, and some patients achieve complete seizure freedom. Ongoing pharmacodynamic research continues to elucidate its precise binding interactions and potential neuroprotective effects, suggesting a promising role in broader epilepsy management.

Pharmacological Actions

Inhibition of voltage-gated sodium channels resulting in reduced neuronal excitability.
Positive allosteric modulation of GABAA ion channels enhancing inhibitory neurotransmission.
Suppression of persistent sodium currents to prevent sustained neuronal depolarizations.
Reduction in frequency and severity of partial-onset seizures in adult patients.
Potential neuroprotective effects by stabilizing neuronal membrane potentials.
Once-daily oral administration providing sustained anticonvulsant activity.
Minimal sedative properties relative to other anticonvulsants.
Schedule V controlled substance due to potential for limited physical or psychological dependence.

Therapeutic Or Clinical Uses

Adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy.
Monotherapy for partial-onset seizures in adults where applicable.
Management of focal seizures originating from a localized brain region.
Reduction of seizure frequency and improvement of quality of life in adult epilepsy patients.
Treatment option for patients intolerant or refractory to other antiepileptic drugs.
Potential use in preventing seizure recurrence during epilepsy maintenance therapy.
Supportive therapy to complement multi-drug regimens targeting diverse seizure mechanisms.

Side Or Adverse Effects

Common side effects: fatigue, dizziness, drowsiness, double vision, and headache.
Serious allergic reactions involving rash, hives, swelling of face or throat, and difficulty breathing.
Potential for severe hypersensitivity reactions affecting liver, blood cells, or other organs.
Cardiac conduction abnormalities such as short QT syndrome or arrhythmias.
Nervous system disturbances including dizziness, loss of coordination, vision problems, and memory issues.
Possible mood and behavioral changes including depression, anxiety, irritability, agitation, and suicidal thoughts.
Muscle pain and weakness potentially signaling systemic allergic response.
Unusual bruising or bleeding indicating hematological side effects.
Gastrointestinal disturbances and infections that do not resolve with treatment.
Withdrawal seizures or increased seizure frequency if therapy is abruptly discontinued.

Precautions

Do not use in patients with known allergy to cenobamate or formulation components.
Contraindicated in individuals with genetic short QT syndrome due to risk of cardiac arrhythmias.
Monitor patients for mood changes and suicidal ideation, especially during titration phase.
Gradually taper dosing under medical supervision to prevent withdrawal seizures.
Use caution in patients with hepatic or renal impairment; monitor function regularly.
Pregnancy use only if potential benefits justify potential risks; enrollment in pregnancy registry recommended.
Avoid concomitant use with other CNS depressants without medical guidance due to additive sedative effects.
Be vigilant for signs of severe rash or hypersensitivity syndromes warranting drug discontinuation.
Advise women of childbearing potential to use effective non-hormonal contraception while on Xcopri.
Ensure adherence to prescribed incremental dosing to reduce risk of serious adverse reactions.

Warnings

Risk of serious or life-threatening allergic reactions involving skin, liver, and blood cells.
Potential for severe cardiac conduction abnormalities; baseline and follow-up ECG may be indicated.
May cause suicidal thoughts or behaviors; close monitoring of psychiatric status is essential.
Abrupt discontinuation can lead to increased seizure frequency or status epilepticus.
Sedation and dizziness risk may impair ability to drive or operate machinery.
Use with caution in pregnancy and breastfeeding due to limited safety data.
Potential for drug abuse or dependence as a Schedule V controlled substance.
Concomitant use with other CNS depressants can exacerbate sedation or respiratory depression.
Dose titration beyond recommended increments increases risk of severe adverse reactions.
Patients should be instructed to seek immediate medical attention if symptoms of hypersensitivity occur.

Contraindication

Known hypersensitivity to cenobamate or any ingredient in Xcopri formulations.
Patients with short QT syndrome, a congenital cardiac conduction disorder.
History of severe allergic reactions to carbamate anticonvulsants.
Concurrent use with drugs known to prolong QT interval in vulnerable patients (caution advised).
Use in pediatric patients under 18 years of age is not indicated due to lack of safety data.

Drug Interactions

Phenytoin and phenobarbital may have altered plasma levels when coadministered with cenobamate.
Clobazam metabolism can be affected, potentially increasing sedation or side effects.
Concomitant use with lamotrigine may modify seizure control or adverse event profiles.
Carbamazepine levels may be influenced, necessitating monitoring of therapeutic levels.
CYP2B6 substrates may interact due to modulation of metabolic pathways by cenobamate.
CYP3A substrates like certain statins or hormonal contraceptives may have decreased effectiveness.
CYP2C19 substrates including some antidepressants and proton pump inhibitors may be affected.
Use with opioid medications, muscle relaxers, or benzodiazepines can increase CNS depression.
Xcopri can reduce efficacy of hormonal birth control; alternative contraception is advised.
Concurrent use with other CNS depressants or alcohol can exacerbate sedation and dizziness.
Potential pharmacokinetic interactions warrant close clinical monitoring during polytherapy.

Preparations Of The Drug

Active ingredient: cenobamate in specified oral tablet strengths (12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg).
Inactive ingredients include colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate.
Colorants for tablets differ by strength: 25 mg and 100 mg tablets contain FD&C Blue #2/indigo carmine aluminum lake, iron oxide red and yellow; 50 mg tablets contain iron oxide yellow; 150 mg and 200 mg tablets contain iron oxide red and iron oxide yellow.
Other excipients include polyethylene glycol 3350, polyvinyl alcohol partially hydrolyzed, talc, and titanium dioxide to create film coating.
Tablets are film-coated and scored to allow dose flexibility and facilitate crushing if necessary.
Formulations are designed to permit administration as whole tablets, crushed oral suspensions, or via nasogastric tube for patients with swallowing difficulties.
Manufactured by SK Life Science, Inc. under strict pharmaceutical quality controls.